NEW YORK (GenomeWeb) – Biocept today announced it has reached agreements with preferred provider organizations Stratose and Galaxy Health Network, who cover 12 million members combined, to provide access to the firm's non-invasive liquid biopsy testing.
The deals bring the total number of Americans with covered access to Biocept's tests to about 31 million. Stratose's network of providers include more than 850,000 direct and affiliate medical, dental, and workers' compensation provider contracts, while GHN's network is made up of 400,000 directly contracted physicians, facilities, and hospitals.
San Diego-based Biocept offers blood-based liquid biopsy tests for use by healthcare providers to monitor patients with recurrent and metastatic cancers and to aid in making treatment decisions. Among the biomarkers covered by the firm's tests are HER2, ER, ALK, FGFR1, MET, EGFR, KRAS, and BRAF.
Last month, Biocept launched its Target Selector assays for use when tissue biopsies are inadequate, or when a surgery may be too dangerous to a patient.